Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

P2 Immune Disorder HSCT Protocol NCT01821781

Uses melphalan as part of myeloablative treatment

Purpose This study hypothesizes that a reduced intensity immunosuppressive preparative regimen will establish engraftment of donor hematopoietic cells with acceptable early and delayed toxicity in patients with immune function disorders. A regimen that maximizes host immune suppression is expected to reduce graft rejection and optimize donor cell engraftment.

ps this study is being run at Washington University School of Medicine which is also running an Evomela study I listed previously.